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 Graphene has emerged as a 2D material with  interesting 
physical properties.1,2 Intensive research is on-going to investigate 
the quantum physics in this system and potential applications for 
nano-electronic devices2, transparent conductors and nano-
composite materials3. Thus far, little has been done to explore 
graphene in biological systems, despite much effort in the area of 
carbon nanotubes for in vitro and in vivo biological applications.4-
9 Here, we synthesize and functionalize nanoscale graphene oxide 
(NGO) sheets (<50nm) by branched, biocompatible polyethylene 
glycol (PEG) to render high aqueous solubility and stability in 
physiological solutions including serum. We then uncover a 
unique ability of graphene in attaching and delivery of aromatic, 
water insoluble drugs.  
It is known that clinical use of various potent, hydrophobic 
molecules (many of them aromatic) is often hampered by their 
poor water solubility. Although synthesis of water soluble pro-
drugs may circumvent the problem, the efficacy of the drug 
decreases. Here, we show that PEGylated NGO (NGO-PEG) 
readily complexes with a water insoluble aromatic molecule 
SN38, a camptothecin (CPT) analog,10 via non-covalent van der 
Waals interaction. The NGO-PEG-SN38 complex exhibits 
excellent aqueous solubility and retains the high potency of free 
SN38 dissolved in organic solvents. The toxicity exceeds that of 
irinotecan (CPT-11, a FDA approved SN38 prodrug for colon 
cancer treatment) by 2-3 orders of magnitude.  
We prepared graphene oxide by oxidizing graphite using a 
modified Hummer’s method.3,11 The resulting GO (single layered 
and few-layered, Supp Info. Fig.S1) was soluble in water but 
aggregated in solutions rich in salts or proteins such as cell 
medium and serum (Fig. 1a). This was likely due to screening of the electrostatic charges and non-specific binding of proteins on 
the GO.12 To impart aqueous stability and prevent bio-fouling, we 
sonicated the GO to make them into small pieces and conjugated 
a 6-armed PEG-amine stars to the carboxylic acid groups3 (Supp 
Info Fig. S3) on GO via carbodiimide catalyzed amide formation. 
The resulting PEGylated NGO exhibited excellent stability in all 
biological solutions tested including serum (Fig. 1b). PEGylation 
was further confirmed by infrared (IR) spectroscopy (Supp Info. 
Fig.S1b). The as-made GO sheets were 50-500nm in size (Fig.1c), 
whereas NGO-PEG was ~5-50 nm (Fig. 1d) due to sonication 
steps (see Supp Info.).  
We then investigated the binding of SN38 to NGO-PEG. We 
chose SN38 as a cargo because SN38 is a potent topoisomerase I 
inhibitor.10 To be active, CPT-11 currently used in clinic has to be 
metabolized to SN38 after systematic adminsitration.10,13 
However a large amount of CPT-11 is excreted before 
transforming to SN38 or metabolized to other inactive 
compounds.14 The water insolubility has prevented the direct use 
of SN38 in the clinic.10 
We found that SN38 was complexed with NGO-PEG (Fig.2a) 
by simple mixing of SN38 dissolved in DMSO with a NGO-PEG 
water solution. The excess, uncoupled SN38 precipitated and was 
GO 
   NGO-PEG 
Water PBS Cell  
medium 
Serum 
(a) 
(b) 
(c) 
(d) 
Figure 1. PEGylation of graphene oxide. (a&b), photos of GO (a) and 
NGO-PEG (b) in different solutions recorded after centrifugation at 
10,000 g for 5 minutes. GO crashed out slightly in PBS and completely in 
cell medium and serum (top panel). NGO-PEG was stable in all solutions. 
(c&d) AFM images of GO (c) and NGO-PEG (d).  
Figure 2. SN38 loading on NGO-PEG. (a) schematic draw of  SN38 
loaded NGO-PEG. Inset: a photo of NGO-PEG-SN38 water solution. (b) 
UV-VIS absorption spectra of NGO-PEG, NGO-PEG-SN38, SN38 in 
methanol and difference spectrum of NGO-PEG and NGO-PEG-SN38. 
The SN38 absorbance at 380 nm was used to determine the loading. (c) 
Fluorescence spectra of SN38 and NGO-PEG-SN38 at [SN38]=1µM. 
Significant fluorescence quenching was observed for SN38 adsorbed on
NGO. (d) Retained SN38 on NGO-PEG over time incubated in PBS and 
serum respectively. SN38 loaded on NGO-PEG was stable in PBS and 
released slowly in serum. Error bars were based on triplet samples.
 removed by centrifugation. Repeated washing and filtration were 
used to remove DMSO and any residual free SN38 (see Supp Info. 
for details). UV-VIS spectrum of the resulting solution revealed 
SN38 peaks superimposing with the absorption curve of NGO-
PEG (Fig. 2b), suggesting loading of SN38 onto NGO-PEG. 
Based on the extinction coefficients, we estimated that 1 gram of 
NGO-PEG loaded ~0.1 gram of SN38 (Supp Info.). An increase 
in sheet thickness was observed after SN38 loading on NGO-PEG 
(Supp Info. Fig. S3). A control experiment revealed no loading of 
SN38 on PEG polymer in a solution free of NGO. 
Unlike free SN38, which was very insoluble in water, NGO-
PEG-SN38 complexes were water soluble at concentrations up to 
~1 mg/mL (in terms of SN38). Fluorescence spectra of NGO-
PEG-SN38 and free SN38 at the same SN38 concentration 
showed drastic fluorescence quenching of SN38 in the NGO-
PEG-SN38 case (Fig.2c), suggesting close proximity of SN38 to 
the NGO sheets. We suggest that binding of SN38 onto NGO-
PEG was non-covalent in nature, driven by hydrophobic 
interactions and π- π stacking15,16 between SN38 and aromatic 
regions of the graphene oxide sheets. The existence of aromatic 
conjugated domains on GO was revealed by NMR previously17 
To determine the stability of SN38 loaded on NGO-PEG and 
release rate, we incubated NGO-PEG in phosphate buffer saline 
(PBS) and mouse serum respectively at 37 ºC and measured the 
percentage of retained SN38 on NGO-PEG (Fig. 2d, See Supp 
Info. for experimental details). We found that SN38 on NGO-
PEG exhibited negligible release from NGO in PBS and ~30% 
release in serum in 3 days (Fig.2d). This suggested strong non-
covalent binding of SN38 on graphene oxide sheets. The slow but 
finite release of SN38 in serum was likely caused by the binding 
of SN38 by serum proteins,18 useful for drug delivery.  
MTS assay found that NGO-PEG-SN38 afforded highly potent 
cancer cell killing in vitro with a human colon cancer cell line 
HCT-116. The water soluble drug CPT-11 was found to be the 
least toxic, with a 50% growth inhibition concentration (IC50) of 
~10 µM (Fig. 3). Our water soluble NGO-PEG-SN38 exhibited 
high potency with IC50 values of ~6nM for HCT-116 cells, which 
is ~ 1000 fold more potent than CPT-11 and similar to that of free 
SN38 dissolved in DMSO (Fig. 3a). The high potency of NGO-
PEG-SN38 was also observed with various other cancer cell lines 
tested (Supp Info. Table S1). Importantly, no obvious toxicity 
was measured for various concentrations of plain NGO-PEG 
without drug loading (Fig.3b), suggesting that the PEGylated 
nanographene oxide sheets were not cytotoxic by themselves. 
Apoptosis assay further confirmed no obvious increase of cell 
death or apoptosis after incubating cells with plain NGO-PEG 
(Supp Info. Fig. S 4). The cellular uptake of NGO-PEG was likely 
via endocytosis as evidenced by confocal fluorescence 
microscopy data (Supp Info. Fig. S5). 
We found that the strategy of attaching various types of 
insoluble, aromatic drug molecules onto NGO-PEG via simple 
adsorption was general. Other drugs that we succeeded in loading 
onto NGO-PEG by simple adsorption included different 
camptothecin analogs and Iressa (geftinib), an potent epidermal 
growth factor receptor (EGFR) inhibitor (Supp Info. Fig. S6&7).  
The water soluble NGO-PEG-SN38 complex could open up a 
window to potential use of this drug. Graphitic nanocarriers 
including nanographene sheets and carbon nanotubes afford 
strong noncovalent binding with aromatic drugs via simple 
adsorption.16 Graphene sheets as drug carrier are interesting 
because both sides of a single sheet could be accessible for drug 
binding. The unique 2D shape and ultra-small size (down to 5 nm) 
of NGO-PEG may offer interesting in vitro and in vivo behaviors. 
Moreover, the low cost and large production scale of graphite and 
GO is unmatched by carbon nanotubes. Thus the biocompatible 
nanographene sheets are novel materials promising for biological 
applications. 
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Figure 3. In vitro cell toxicity assay. (a) Relative cell viability (versus 
untreated control) data of HCT-116 cells incubated with CPT-11, 
SN38 and NGO-PEG-SN38 at different concentrations for 72 h. Free 
SN38 was dissolved in DMSO and diluted in PBS. Water soluble 
NGO-PEG-SN38 showed similar toxicity as SN38  in DMSO and far 
higher potency than CPT-11. (b) Relative cell viability data of HCT-
116 cells after incubation with NGO-PEG with (red) and without 
(black) SN38 loading. Plain NGO-PEG exhibited no obvious toxicity 
even at very high concentrations. Error bars were based on triplet 
samples.
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